Posted on 7/18/19
Abeona Therapeutics: A True Test Looms As Cash Dwindles
SummaryValuation of Abeona Therapeutics has suffered in the last few months by means of catalyst setbacks and dwindling cash runway.A technical glance at Abeona's price chart . . .
Posted on 7/18/18
Zynerba's Therapeutics And Data Lack Conviction
SummaryThere are no FDA-approved therapies for Fragile X Syndrome.ZYN002 appears to have demonstrated meaningful and overwhelming efficacy data in a phase 2 trial.There are, however, disclaimers . . .
Posted on 6/26/18
Zafgen: 3 Key Takeaways From ADA Abstracts
Zafgen (ZFGN) released three abstracts at the American Diabetes Association conference. Amongst them included full results in a phase 2 proof-of-concept trial assessing ZGN-1061 in uncontrolled . . .

